Table 2.
All toxicities that occurred in at least 5% of patients and were related to atrasentan by dose level (n = 25)
| Dose Level (mg)
|
|||||||
|---|---|---|---|---|---|---|---|
| Toxicity | 10 (n = 2) | 20 (n = 2) | 30 (n = 4) | 50 (n = 3) | 70 (n = 11) | 90 (n = 3) | Overall Percentage of Patients |
| Nausea | 1 | 1 | 8% | ||||
| Vomiting | 1 | 1 | 8% | ||||
| Weight gain | 1 | 1 | 8% | ||||
| ANC | 1 | 1 | 8% | ||||
| Hypocalcemia | 2 | 8% | |||||
| Platelets | 1 | 1 | 8% | ||||
| SGPT | 1 | 1 | 8% | ||||
| Arthralgia | 1 | 1 | 1 | 12% | |||
| Constipation | 1 | 1 | 1 | 12% | |||
| Headache | 1 | 2 | 12% | ||||
| Low WBC | 2 | 1 | 12% | ||||
| Dyspnea | 1 | 2 | 1 | 16% | |||
| Dry mouth | 1 | 1 | 1 | 1 | 16% | ||
| Hemoglobin | 1 | 4 | 1 | 24% | |||
| Allergic rhinitis | 1 | 1 | 1 | 4 | 28% | ||
| Edema | 3 | 5 | 1 | 36% | |||
| Fatigue | 1 | 2 | 2 | 3 | 3 | 1 | 48% |
Abbreviations: ANC, absolute neutrophil count; SGPT, serum glutamic pyruvic transaminase; WBC, white blood count.